Commodity Channel Index
|Bid||178.20 x 900|
|Ask||178.30 x 1100|
|Day's Range||170.55 - 181.55|
|52 Week Range||121.80 - 194.93|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||165.20|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||184.00|
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the pricing of an underwritten public offering of 753,012 shares of its common stock at a price to the public of $166.00 per share. All of the shares of common stock to be sold in the offering will be offered by Penumbra. The offering is scheduled to close on June 1, 2020, subject to customary closing conditions. The underwriters for the offering will also have a 30-day option to purchase up to an additional 112,951 shares of Penumbra's common stock at the public offering price, less underwriting discounts and commissions.
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by Penumbra. In addition, Penumbra expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of Penumbra's common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Penumbra, Inc. (NYSE: PEN) today announced that the format for its 2020 Annual Meeting of Stockholders (the "Annual Meeting") has been changed from an in-person meeting to a virtual-only meeting at the previously announced date and time of June 3, 2020 at 11:00 a.m. Pacific Time due to the public health concerns related to the COVID-19 pandemic and to support the health and safety of its stockholders, employees and other meeting participants. The Annual Meeting will be conducted solely via live audio webcast, and stockholders will not be able to attend the Annual Meeting at a physical location. However, stockholders of record as of the close of business on April 15, 2020 (the "Record Date") will have the ability to attend the Annual Meeting, vote their shares and ask questions during the Annual Meeting.
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that Sri Kosaraju, President, will transition from Penumbra, and Jason Mills joins as Executive Vice President, Strategy. Mr. Kosaraju will continue as an employee over the next several months to ensure a seamless transition, while volunteering substantial time to Testing for America, a nonprofit established by leading academics, engineers, and entrepreneurs to address the COVID-19 testing crisis. Mr. Kosaraju has stepped down as President, and Adam Elsesser has been reappointed to the position. Mr. Mills joins Penumbra effective May 12, 2020.
At this time, I would like to welcome everyone to the Penumbra's First Quarter 2020 Conference Call. It is now my pleasure to turn the conference over to Ms. Jee Hamlyn-Harris, Investor Relations for Penumbra. Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the first quarter 2020.
Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, 2020.
Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2020 after market close on Thursday, May 7, 2020 at 5:00 PM Eastern Time. A press release with first quarter 2020 financial results will be issued after market close that day.
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today provided an update on the actions it is taking to focus its business operations to support employees, physicians, and patients in response to the coronavirus (COVID-19) pandemic. Penumbra is also providing a preliminary range for its first quarter 2020 revenue and withdrawing its annual revenue guidance for 2020 due to the potential impact of COVID-19.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
HTC VIVE®, the leader in premium virtual reality (VR), and Penumbra (NYSE: PEN), a global healthcare company focused on innovative therapies, announced today that Penumbra's new solution for stroke recovery, the REAL™ Immersive System (REAL System) is using a custom-designed VIVE Focus™ head mounted display to help patients recover from stroke and other neurological injury.
In two separate deals, much of the campus developed for tech firm Hewlett Packard Enterprise in Roseville has sold, for more than $140 million combined.
Penumbra (PEN) delivered earnings and revenue surprises of 22.22% and 2.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN), based in Alameda, Ca., provides health services focused on interventional therapies; technically, the stock has broken out from a 10-week, double bottom base, notes Leo Fasciocco, editor of Ticker Tape Digest.
Today we are going to look at Penumbra, Inc. (NYSE:PEN) to see whether it might be an attractive investment prospect...